Shares of Edgewise Therapeutics, Inc. (EWTX) are surging more than 40% in Friday morning trade.
The company has announced pricing 21,818,182 of its shares at $11 per share. It intends to use the proceeds to support the potential U.S. commercial launch of EDG-5506 in patients with Becker muscular dystrophy, completion of Phase 2 trials of EDG-7500 in patients with hypertrophic cardiomyopathy, among others.
EDG-5506 is in clinical trials in patients with Becker, Duchenne, and Limb-Girdle muscular dystrophies as well as McArdle Disease. EDG-7500 is currently in a Phase 1 trial.
EWTX is at $13.58 currently. It has traded in the range of $5.12 - $13.32 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.